PERSONALIS INC (PSNL)
US71535D1063 - Common Stock
Overall PSNL gets a fundamental rating of 2 out of 10. We evaluated PSNL against 58 industry peers in the Life Sciences Tools & Services industry. PSNL has a bad profitability rating. Also its financial health evaluation is rather negative. PSNL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PSNL had negative earnings in the past year.
In the past year PSNL has reported a negative cash flow from operations.
In the past 5 years PSNL always reported negative net income.
In the past 5 years PSNL always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -48.11%, PSNL is doing worse than 89.66% of the companies in the same industry.
PSNL has a Return On Equity of -83.67%. This is amonst the worse of the industry: PSNL underperforms 81.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.11% | ||
| ROE | -83.67% | ||
| ROIC | N/A |
ROA(3y)-34.43%
ROA(5y)-27.22%
ROE(3y)-52.21%
ROE(5y)-40.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PSNL's Gross Margin of 24.77% is on the low side compared to the rest of the industry. PSNL is outperformed by 86.21% of its industry peers.
In the last couple of years the Gross Margin of PSNL has declined.
PSNL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-4.55%
2. Health
2.1 Basic Checks
PSNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PSNL has more shares outstanding
Compared to 5 years ago, PSNL has more shares outstanding
PSNL has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.96, we must say that PSNL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PSNL (-2.96) is worse than 87.93% of its industry peers.
PSNL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.01, PSNL is doing good in the industry, outperforming 70.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.96 |
ROIC/WACCN/A
WACC12.29%
2.3 Liquidity
PSNL has a Current Ratio of 3.11. This indicates that PSNL is financially healthy and has no problem in meeting its short term obligations.
PSNL has a Current ratio (3.11) which is in line with its industry peers.
PSNL has a Quick Ratio of 2.88. This indicates that PSNL is financially healthy and has no problem in meeting its short term obligations.
PSNL has a Quick ratio (2.88) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.11 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
PSNL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.11%, which is quite good.
The Revenue has grown by 12.97% in the past year. This is quite good.
PSNL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.24% yearly.
EPS 1Y (TTM)14.11%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q19.4%
Revenue 1Y (TTM)12.97%
Revenue growth 3Y-2.24%
Revenue growth 5Y14.24%
Revenue growth Q2Q17.67%
3.2 Future
The Earnings Per Share is expected to grow by 17.55% on average over the next years. This is quite good.
Based on estimates for the next years, PSNL will show a very strong growth in Revenue. The Revenue will grow by 36.80% on average per year.
EPS Next Y24.31%
EPS Next 2Y16.28%
EPS Next 3Y15.31%
EPS Next 5Y17.55%
Revenue Next Year0.95%
Revenue Next 2Y8.16%
Revenue Next 3Y16.24%
Revenue Next 5Y36.8%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PSNL. In the last year negative earnings were reported.
Also next year PSNL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PSNL's earnings are expected to grow with 15.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.28%
EPS Next 3Y15.31%
5. Dividend
5.1 Amount
No dividends for PSNL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PERSONALIS INC
NASDAQ:PSNL (5/2/2024, 7:14:45 PM)
Premarket: 1.52 -0.08 (-5%)1.6
+0.05 (+3.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap81.94M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.11% | ||
| ROE | -83.67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.77% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.11 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)14.11%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y24.31%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)12.97%
Revenue growth 3Y-2.24%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y